Cancer immunotherapy technologies based on T cells, such as immune checkpoint inhibitors, direct the immune system to attack malignant cells. ImmuneXcite Inc. is developing a novel cancer immunotherapy platform technology that entices another more abundant immune cell type, neutrophils, to engulf and destroy malignant cells as well as activate T cells, an approach that could also prove useful in combination with T-cell-based immunotherapeutic approaches.
UK-based start-up Inivata Ltd. is using cell-free circulating tumor DNA (ctDNA), found in the bloodstream, to create a “liquid...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?